Improving treatment for cancer patients by reducing nerve damage from vincristine
Official title: Targeting neuronal transport to ameliorate vincristine neurotoxicity
Funded at Ohio State University · NIH-10886140 · Data updated 2026-11-12
This study is looking at how the chemotherapy drug vincristine can harm nerves in cancer patients, and it aims to find ways to protect those nerves while still allowing the drug to fight cancer effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | July 11, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $620,870 |
| NIH project number | 5R01CA272254-02 |
| Project ID | NIH-10886140 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients, particularly those receiving vincristine treatment for acute leukemia or other solid tumors.
✕Less likely to help
Patients who are not undergoing treatment with vincristine or those with conditions unrelated to chemotherapy may not benefit from this research.
What this research studies
This research investigates how vincristine, a common chemotherapy drug, causes nerve damage in patients with cancer. The study focuses on understanding the transport mechanism of vincristine into nerve cells and aims to identify ways to prevent this neurotoxicity. By exploring specific transport proteins that facilitate vincristine's entry into dorsal root ganglion neurons, the researchers hope to find existing medications that can protect these neurons without affecting the drug's cancer-fighting properties. This approach could lead to safer chemotherapy treatments for patients.
Why it matters
Potential benefit: If successful, this research could significantly reduce nerve damage in cancer patients receiving vincristine, improving their quality of life.
How similar studies have gone: Previous research has shown promise in using pharmacological inhibitors to mitigate drug-related neurotoxicity, suggesting that this approach may be effective.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Hu, Shuiying — Ohio State University
- Study coordinator: Hu, Shuiying
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.